Bedoukian   RussellIPM   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Alphascents
Pherobio
InsectScience
E-Econex
Counterpart-Semiochemicals
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous Abstract"Investigation of paediatric PKU breath malodour, comparing glycomacropeptide with phenylalanine free L-amino acid supplements"    Next AbstractFunctional analysis of a tomato salicylic acid methyl transferase and its role in synthesis of the flavor volatile methyl salicylate »

J Breath Res


Title:Breath-based non-invasive diagnosis of Alzheimer's disease: a pilot study
Author(s):Tiele A; Wicaksono A; Daulton E; Ifeachor E; Eyre V; Clarke S; Timings L; Pearson S; Covington JA; Li X;
Address:"School of Engineering, University of Warwick, Coventry CV4 7AL, United Kingdom"
Journal Title:J Breath Res
Year:2020
Volume:20200214
Issue:2
Page Number:26003 -
DOI: 10.1088/1752-7163/ab6016
ISSN/ISBN:1752-7163 (Electronic) 1752-7155 (Linking)
Abstract:"Early detection of Alzheimer's disease (AD) will help researchers to better understand the disease and develop improved treatments. Recent developments have thus focused on identifying biomarkers for mild cognitive impairment due to AD (MCI) and AD during the preclinical phase. The aim of this pilot study is to determine whether exhaled volatile organic compounds (VOCs) can be used as a non-invasive method to distinguish controls from MCI, controls from AD and to determine whether there are differences between MCI and AD. The study used gas chromatography-ion mobility spectrometry (GC-IMS) techniques. Confounding factors, such as age, smoking habits, gender and alcohol consumption are investigated to demonstrate the efficacy of results. One hundred subjects were recruited including 50 controls, 25 AD and 25 MCI patients. The subject cohort was age- and gender-matched to minimise bias. Breath samples were analysed using a commercial GC-IMS instrument (G.A.S. BreathSpec, Dortmund, Germany). Data analysis indicates that the GC-IMS signal was consistently able to separate between diagnostic groups [AUC +/- 95%, sensitivity, specificity], controls versus MCI: [0.77 (0.64-0.90), 0.68, 0.80], controls versus AD: [0.83 (0.72-0.94), 0.60, 0.96], and MCI versus AD: [0.70 (0.55-0.85), 0.60, 0.84]. VOC analysis indicates that six compounds play a crucial role in distinguishing between diagnostic groups. Analysis of possible confounding factors indicate that gender, age, smoking habits and alcohol consumption have insignificant influence on breath content. This pilot study confirms the utility of exhaled breath analysis to distinguish between AD, MCI and control subjects. Thus, GC-IMS offers great potential as a non-invasive, high-throughput, diagnostic technique for diagnosing and potentially monitoring AD in a clinical setting"
Keywords:"Aged Alzheimer Disease/*diagnosis Biomarkers/analysis Breath Tests/*methods Case-Control Studies Cognitive Dysfunction/diagnosis Confounding Factors, Epidemiologic *Early Diagnosis Female Gas Chromatography-Mass Spectrometry Humans Ion Mobility Spectromet;"
Notes:"MedlineTiele, Akira Wicaksono, Alfian Daulton, Emma Ifeachor, Emmanuel Eyre, Victoria Clarke, Sophie Timings, Leanne Pearson, Stephen Covington, James A Li, Xinzhong eng Research Support, Non-U.S. Gov't England 2019/12/10 J Breath Res. 2020 Feb 14; 14(2):026003. doi: 10.1088/1752-7163/ab6016"

 
Back to top
 
Citation: El-Sayed AM 2024. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2024 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 29-06-2024